Dr. Laforce obtained his PhD in Clinical Neuropsychology in 1998 and worked as an Assistant Professor in Cognitive Neurosciences before completing his studies in Behavioral Neurology in 2011. He performed a short Fellowship in frontotemporal dementia under Dr. Bruce Miller at the Memory and Aging Center, University of California San Francisco. He conducted brain imaging studies using FDG-PET and amyloid PET with Dr. Gil Rabinovici (University of California, Berkeley). He was co-leader of the Neurology class at Laval University for 5 years. He is a Clinician and Researcher in CHU de Québec Research Center, member of the C5R (Consortium of Canadian Centres for Clinical Cognitive Research) and RQRV (Réseau Québécois de Recherche sur le Vieillissement). Dr. Laforce obtained several major grants (CIHR, Weston Brain Institute), presented at national and international meetings, published over 100 scientific papers in prestigious journals such as Lancet Neurology, Brain, Neurology. He wrote a book on memory as well as several book chapters. Dr. Laforce is one of the PIs in the great international endeavour GENFI (Genetic Frontotemporal Dementia Initiative) and DIAN (Dominantly Inherited Alzheimer Network). He leads several research projects on the development of cognitive tools (www.dcqtest.org et www.quoco.org) and the clinical utility of molecular imaging such as FDG-PET and amyloid PET in the differential diagnosis of atypical dementias. He holds the Chaire de Recherche sur les Aphasies Primaires Progressives – Fondation Famille Lemaire (https://app-ffl.ulaval.ca/).
Clinique Interdisciplinaire de Mémoire
S-0071
Québec, Québec
Canada G1J 1Z4
Latest news
- [ULaval Nouvelles] COVID-19: des effets persistants sur le goût et l’odorat chez le tiers des personnes infectées 2022-05-30
- [Le Chuchoteur] Soins, enseignement et recherche : des neurones bien connectés 2021-04-27
- [Conférence] Alzheimer et troubles neurocognitifs atypiques, avec le Dr Robert Jr Laforce 2021-01-25
- Aoudia, RabahEmployee
- Bourgeois, Mary ChristineEmployeemary-christine.bourgeois@chudequebec.camary-christine.bourgeois@crchudequebec.ulaval.ca
- Carrier-Auclair, JulieMaster student
- Cyr, NancyEmployeeHôpital de l'Enfant-Jésus+1 418-525-4444, extension 63442
1401 18e Rue
Clinique de mémoire
Québec, QC
Canada G1J 1Z4 - Drouin, LaurenceEmployeelaurence.drouin@crchudequebec.ulaval.ca
- Foster, ChloéEmployee
- Gagnon, AmélyEmployeeamely.gagnon@crchudequebec.ulaval.ca
- Gagnon, AmélyEmployeeamely.gagnon@crchudequebec.ulaval.ca
- Lavoie, MonicaEmployeeHôpital de l'Enfant-Jésus+1 418-525-4444, extension 61058monica.lavoie@crchudequebec.ulaval.ca
1401 18e Rue
S-0069
Québec, QC
Canada G1J 1Z4 - Légaré, AnnieEmployeeHôpital de l'Enfant-Jésusannie.legare@crchudequebec.ulaval.ca
1401 18e Rue
Québec, QC
Canada G1J 1Z4 - Plourde, RoseEmployee
- Poulin, AnnabelleEmployeeannabelle.poulin@crchudequebec.ulaval.ca
- Poulin, ElizabethEmployee+1 418-525-4444, extension 66729elizabeth.poulin@crchudequebec.ulaval.ca
- Roy, CassandraMaster studentcassandra.roy.6@ulaval.cacassandra.roy@crchudequebec.ulaval.ca
- Roy, CassandraEmployeecassandra.roy.6@ulaval.cacassandra.roy@crchudequebec.ulaval.ca
- Roy-Clavel, Anne-SophieMaster student
- Tastevin, MaudFellow
- Wu, FeiMaster studentfei.wu@crchudequebec.ulaval.ca
Distinct spatial contributions of amyloid pathology and cerebral small vessel disease to hippocampal morphology
Journal ArticleAlzheimers Dement, 20 (5), 2024.
A cross-cultural study of the Montreal Cognitive Assessment for people with hearing impairment
Journal ArticleJ Am Geriatr Soc, 72 (10), 2024.
Efficacy of LSVT LOUD® on Phonatory Control and Voice Quality in Patients with Primary Progressive Apraxia of Speech: Case Studies
Journal ArticleBrain Sci, 14 (5), 2024.
Efficacy of LSVT LOUD® on Phonatory Control and Voice Quality in Patients with Primary Progressive Apraxia of Speech: Case Studies
Journal ArticleBrain Sci, 14 (5), 2024.
Extending the phenotypic spectrum assessed by the CDR plus NACC FTLD in genetic frontotemporal dementia
Journal ArticleAlzheimers Dement (Amst), 16 (2), 2024.
Longitudinal cerebral perfusion in presymptomatic genetic frontotemporal dementia: GENFI results
Journal ArticleAlzheimers Dement, 20 (5), 2024.
Diagnostic accuracy of research criteria for prodromal frontotemporal dementia
Journal ArticleAlzheimers Res Ther, 16 (1), 2024.
The impact of phonological short-term memory impairment on verbal repetition in the logopenic variant of primary progressive aphasia
Journal ArticleNeuropsychol Dev Cogn B Aging Neuropsychol Cogn, 31 (4), 2024.
Comparative accuracy of Mini-Linguistic State Examination, Addenbrooke's Cognitive Examination, and Depistage Cognitif de Quebec for the diagnosis of primary progressive aphasia
Journal ArticleJ Alzheimers Dis, 102 (1), 2024.
Association of Initial Side of Brain Atrophy With Clinical Features and Disease Progression in Patients With GRN Frontotemporal Dementia
Journal ArticleNeurology, 103 (11), 2024.
Active projects
- Chaire de recherche sur les aphasies primaires progressives, from 2024-07-01 to 2029-06-30
- Genetic Frontotemporal Dementia Initiative (GENFI) in Canada: Combined Investigation of Clinical, MRI, Genomic, and Epigenomic Biomarkers, from 2021-04-01 to 2026-03-31
- L'homocystéine, une molécule utile pour prédire le déclin cognitif dans la maladie de Parkinson et la démence à corps de Lewy, from 2024-06-25 to 2026-09-30
- L'hyperhomocystéinémie:étude de son potentiel comme biomarqueur du déclin cognitif commun à la démence à corps de Lewy et à la maladie de parkinson pour améliorer le diagnostic et le traitement des patients, from 2024-01-23 to 2024-12-31
- Neurodevelopmental vs. Neurodegenerative: A study of neurodevelopmental consequences of FTD genetic mutations in at-risk youth, from 2022-04-01 to 2027-03-31
Recently finished projects
- Chaire de recherche sur les aphasies primaires progressives, from 2019-07-01 to 2024-06-30
- DIAN-TU : A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease, from 2020-06-01 to 2024-05-31
- Phase Two of the Canadian Consortium on Neurodegeneration in Aging, from 2019-04-01 to 2024-03-31